维奈克拉消除新诊断急性髓系白血病中剪接因子基因突变的预后影响
该研究纳入994例新诊断急性髓系白血病患者,其中266例(27%)携带剪接因子基因突变,评估维奈克拉对剪接因子突变预后意义的影响。在强化疗患者中,剪接因子突变者无复发生存期和总生存期原本较短,但接受维奈克拉联合强化疗后该差异不再显著;在低强度治疗患者中,伴或不伴剪接因子突变者生存期相似,且维奈克拉改善所有组别结局。多因素分析显示剪接因子突变在强化疗组不影响复发和死亡风险,在低强度治疗组反而降低这两种风险。
要点
- 剪接因子突变在强化疗患者中与较短无复发生存期和总生存期相关,但加用维奈克拉后该预后影响消失。
- 低强度治疗患者中,伴或不伴剪接因子突变者无复发生存期和总生存期相似。
- 多因素分析显示剪接因子突变在强化疗组不影响复发和死亡风险,在低强度治疗组降低这两种风险。
核心结论
- 在超过60%患者接受维奈克拉联合低强度或强化疗的大型急性髓系白血病数据集中,剪接因子突变无独立不良预后影响。
- 作者认为需要新的预后模型,考虑低强度治疗和维奈克拉使用等因素。
研究设计与样本
- 研究评估994例新诊断急性髓系白血病患者,其中266例(27%)携带剪接因子基因突变。
- 总体中位年龄67岁,剪接因子突变患者年龄更大,为72岁。
- SRSF2突变最常见,共140例(53%)。
主要发现
- 强化疗患者中,剪接因子突变组 vs 无突变组:中位无复发生存期9.6个月 vs 21.4个月(P=.04),中位总生存期15.9个月 vs 26.7个月(P=.06)。
- 接受维奈克拉联合强化疗患者中,剪接因子突变组 vs 无突变组:中位无复发生存期15.4个月 vs 20.3个月(P=.36),中位总生存期19.6个月 vs 30.7个月(P=.98)。
- 低强度治疗患者中,剪接因子突变组 vs 无突变组:中位无复发生存期9.3个月 vs 7.7个月(P=.35),中位总生存期12.3个月 vs 8.5个月(P=.14)。
- 多因素分析显示,剪接因子突变在强化疗组不影响复发和死亡风险,在低强度治疗组降低复发和死亡风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要新的预后模型,考虑低强度治疗和维奈克拉使用等因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) risk stratification. The prognostic impact of SF mutations in AML has been predominantly derived from younger patients treated with intensive (INT) therapy. We evaluated 994 patients with newly diagnosed AML, including 266 (27%) with a SFmut. Median age was 67 years overall, with patients with SFmut being older at 72 years. SRSF2 (n = 140, 53%) was the most common SFmut. In patients treated with INT, median relapse-free survival (RFS) (9.6 vs 21.4 months, P = .04) and overall survival (OS) (15.9 vs 26.7 months, P = .06) were shorter for patients with SFmut than without SFwt, however this significance abrogated when evaluating patients who received venetoclax with INT therapy (RFS 15.4 vs 20.3 months, P = .36; OS 19.6 vs 30.7 months, P = .98). In patients treated with LI, median RFS (9.3 vs 7.7 months, P = .35) and OS (12.3 vs 8.5 months, P = .14) were similar for patients with and without SFmut , and outcomes improved in all groups with venetoclax. On multivariate analysis, SFmut did not affect hazards of relapse and death for INT arm but reduced both these hazards in LI arm. In a large AML data set with >60% of patients receiving venetoclax with LI/INT therapy, SFmut had no independent negative prognostic impact. Newer prognostic models that consider LI therapy and use of venetoclax among other factors are warranted.
引用
- Senapati J, Urrutia S, Loghavi S, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023. PMID: 37441846. doi:10.1182/blood.2023020649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。